Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C1522282 (
EMT
)
2,868
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Our previous studies showed that
Fibroblast growth factor receptor 3
(
FGFR3
) contributed to cell growth in lung cancer. However, the correlation between
FGFR3
and tumor progression, coupled with the underlying mechanisms, are not fully understood. The clinical significance of
FGFR3
was determined in two cohorts of clinical samples (
n
= 22,
n
= 78). A panel of biochemical assays and functional experiments was utilized to elucidate the underlying mechanisms and effects of
FGFR3
and miR-24-3p on lung adenocarcinoma progression. Upregulated
FGFR3
expression indicated an adverse prognosis for lung adenocarcinoma individuals and promoted metastatic potential of lung adenocarcinoma cells. Owing to the direct regulation towards
FGFR3
, miR-24-3p could interfere with the potential of proliferation, migration, and invasion in lung adenocarcinoma, following variations of
EMT
-related protein expression. As a significant marker of
EMT
, E-cadherin was negatively correlated with
FGFR3
, of which ectopic overexpression could neutralize the antitumour effects of miR-24-3p and reverse its regulatory effects on
EMT
markers. Taken together, these findings define a novel insight into the miR-24-3p/
FGFR3
signaling axis in regulating lung adenocarcinoma progression and suggest that targeting the miR-24-3p/
FGFR3
axis could be an effective and efficient way to prevent tumor progression.
...
PMID:miR-24-3p/FGFR3 Signaling as a Novel Axis Is Involved in Epithelial-Mesenchymal Transition and Regulates Lung Adenocarcinoma Progression. 2985 Jun 25